✦ LIBER ✦

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group

✍ Scribed by Bradley J. Monk; Michael W. Sill; Parviz Hanjani; Robert Edwards; Jacob Rotmensch; Koen De Geest; Albert J. Bonebrake; Joan L. Walker

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel plus trabectedin appears activ

✍ Maurie Markman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 53 KB

A phase II evaluation of mifepristone in

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 162 KB

A phase II evaluation of tirapazamine pl

✍ Allan Covens; John Blessing; David Bender; Robert Mannel; Mark Morgan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Comments on: “Docetaxel plus trabectedin

✍ Michael W. Sill; Bradley J. Monk 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Corrigendum to “A phase II evaluation of

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 90 KB

A phase II evaluation of motesanib (AMG

✍ Schilder, R.J.; Sill, M.W.; Lankes, H.A.; Gold, M.A.; Mannel, R.S.; Modesitt, S. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 189 KB